Cefuroxime efficacy in pneumonia: Sequential short-course iv/oral suspension therapy

I. Shalit, R. Dagan, D. Engelhard, M. Ephros, K. Cuningham

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


For children with acute respiratory infections in hospital, it is desirable to transfer from parenteral to oral therapy at the earliest opportunity. The introduction of a pediatric suspension of cefuroxime axetil provides a continuous course of one antibiotic with transition from injectable to oral therapy. This open study was designed to investigate the efficacy of cefuroxime in pediatric patients aged 3 months to 5 years with community-acquired pneumonia. Children had evidence of lobar pneumonia on chest X-ray, a white blood cell count of >15,000/mm3 and a rectal temperature of ≥38.5°C on enrollment. Cefuroxime was given by i.v. injection at 75 mg/kg per day in three divided doses for 48-72 h followed by oral cefuroxime suspension at 30 mg/kg per day in two divided doses. Of 84 evaluable patients 82 (97.6%) were cured or improved post-treatment, and of 74 evaluable children who returned for follow-up assessment 73 (98.6%) remained well. Oral therapy with twice daily cefuroxime axetii suspension following 2-3 days of i.v. cefilroxime administration was confirmed as effective and safe treatment for lobar pneumonia in children under 5 years of age.

Original languageEnglish
Pages (from-to)684-689
Number of pages6
JournalIsrael Journal of Medical Sciences
Issue number9
StatePublished - 1 Jan 1994
Externally publishedYes


  • Bacterial pneumonia
  • Cefuroxine
  • Cefuroxine axetil
  • Childhood pneumonia
  • Lobar pneumonia

ASJC Scopus subject areas

  • Bioengineering


Dive into the research topics of 'Cefuroxime efficacy in pneumonia: Sequential short-course iv/oral suspension therapy'. Together they form a unique fingerprint.

Cite this